CLARKE DAVID H 4
4 · INNOVATE BIOPHARMACEUTICALS, INC. · Filed Mar 13, 2018
Insider Transaction Report
Form 4
CLARKE DAVID H
DirectorFormer CEO and Director
Transactions
- Purchase
Common Stock
2016-07-13$4.50/sh+15,000$67,500→ 445,043 total - Purchase
Common Stock
2017-03-16$1.50/sh+70,000$105,000→ 690,043 total(indirect: See footnote) - Award
Common Stock
2017-06-30+13,467→ 909,545 total(indirect: See footnote) - Purchase
Common Stock
2017-11-29$0.45/sh+366,159$164,772→ 1,375,704 total(indirect: See footnote) - Award
Common Stock
2017-01-24+175,000→ 620,043 total - Purchase
Common Stock
2017-06-23$0.58/sh+172,414$100,000→ 862,457 total(indirect: See footnote) - Award
Common Stock
2017-11-09+100,000→ 1,009,545 total - Award
Common Stock
2017-06-30+33,621→ 896,078 total(indirect: See footnote) - Award
Common Stock
2018-01-25+25,000→ 1,418,450 total - Purchase
Common Stock
2018-01-26$0.35/sh+300,000$105,000→ 1,718,450 total(indirect: See footnote) - Award
Common Stock
2018-01-24+17,746→ 1,393,450 total(indirect: See footnote)
Footnotes (2)
- [F1]Shares of restricted common stock granted under Issuer's 2012 Omnibus Incentive Plan.
- [F2]Reporting Person's beneficial ownership includes: 71,402 shares of common stock held by his spouse and 1,063,350 shares of common stock held by GSB Holdings, Inc., a corporation owned by his spouse and children.